Coadministration of oral levofloxacin with agents that impair absorption: Impact on antibiotic resistance

Infection Control and Hospital Epidemiology

Volumn 29, Issue 10, 2008, Pages 975-977

  Cohen, Keira A ^a   Lautenbach, Ebbing ^a   Weiner, Mark G ^a   Synnestvedt, Marie ^a   Gasink, Leanne B ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIVALENT CATION; LEVOFLOXACIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; DRUG ABSORPTION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA;

ABSORPTION; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CATIONS; CATIONS, DIVALENT; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; RISK FACTORS;

EID: 53549132504     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/590666     Document Type: Article

References (9)

1. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005; 118:259-268.
2. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38:655-662.
3. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-888.
4. Guay D. Quinolones. In: Piscitelli S, Rodvold K, eds. Drug Interactions in Infectious Diseases. Totowa, NJ: Humana Press; 2001:121-150.
5. Quain RD, Barton TD, Fishman NO, Weiner MG, Lautenbach E. Coadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistance. Int J Antimicrob Agents 2005; 26:327-330.
6. Barton TD, Fishman NO, Weiner MG, LaRosa LA, Lautenbach E. High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infect Control Hosp Epidemiol 2005; 26:93-99.
7. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 16th informational supplement. Wayne, PA: CLSI, 2006:M100-S16.
8. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003; 37:1643-1648.
9. Michea-Hamzehpour M, Auckenthaler R, Regamey P, Pechere JC. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother 1987; 31:1803-1808.